Health AI Central
Share:
Peer-Reviewed Publication
Blood Adv2026June 24, 2026Journal Article

Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.

Carol Fries1, Lingyun Ji2, Meenakshi Devidas3, Karen R Rabin4, Mignon L Loh5, Lik Wee Lee6, Ilan R Kirsch7, David T Teachey8, Sumit Gupta9, Brent L Wood10, Rachel E Rau11
1University of Rochester, Rochester, New York, United States.
2University of Southern California, Keck School of Medicine, Los Angeles, California, United States.
3St Jude Children's Research Hospital, Memphis, Tennessee, United States.
4University of California San Francisco, San Francisco, California, United States.
5Seattle Children's Hospital, the Ben Town Center for Childhood Cancer Research, University of Washington, Seattle, WA., Seattle, Washington, United States.
6Adaptive Biotechnologies Corp., Seattle, Washington, United States.
7Adaptive Biotechnologies, Seattle, Washington, United States.
8Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.
9Hospital for Sick Children, Toronto, Ontario, Canada.
10Childrens Hospital Los Angeles, Los Angeles, California, United States.
11University of Washington/Seattle Children's Hospital, Seattle, Washington, United States.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.